Bacterial lysates as immunostimulants for respiratory infection in children: mechanism of action, efficacy and safety

Cite item

Full Text


The relevance of the use of immunostimulants in the complex treatment of acute and recurrent respiratory infections is beyond doubt. At the same time, a number of factors: unexplored mechanism of action, lack of evidence of efficacy, unexplored safety - inhibit the widespread use of many immunostimulants. In contrast to bacterial lysates, in particular the drug OM-85 (Broncho-Munal®), on the contrary, there are reliable data on good efficacy against both acute and recurrent respiratory infections, evidence of safety and scientific information on the mechanism of action.

Full Text

Restricted Access

About the authors

Mikhail A. Shevyakov

Mechnikov North-Western State Medical University

Saint Petersburg, Russia


  1. Урсова Н.И. Дисбактериозы кишечника в детском возрасте: инновации в диагностике коррекции и профилактике. Руководство для врачей. М., 2013.
  2. Косенко И.М. Иммуномодулирующая терапия заболеваний ротоглотки у детей. Детские инфекции. 2010; 9 (1): 56-61.
  3. Согласованное мнение экспертов IX Образовательного международного консенсуса по респираторной медицине в педиатрии по вопросам применения бактериальных лизатов в педиатрической практике. Под ред. Н.А. Геппе, А.Б. Малахова. Доктор.РУ. Педиатрия. 2020; 19 (3): 61-3.
  4. Kearney SC et al. Immunoregulatory and immunostimulatory responses of bacterial lysates in respiratory infections and asthma. Ann Allergy Asthma Immunol 2015; 114 (5): 364-9.
  5. Zagar S, Lofler-Badzek D. Broncho-Vaxom in children with rhinosinusitis: a doubleblind clinical trial. J Otorhinolaryngol Relat Spec 1988; 50 (6): 397-404.
  6. Dang AT et al. OM-85 is an immunomodulator of interferon-b production and in-flammasome activity. Sci Rep 2017; 7 (43844).
  7. Liu YW, Dong SH, Zhan GY et al. Analysis of the effect of bacterial lysate and the immunologic mechanism in treating infant bronchiolitis. Eur Rev Med Pharmacol Sci 2017; 21 (14): 3332-6.
  8. Rossi GA et al. Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice. Italian J Pediatrics 2018; 44 (1): 112.
  9. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJL. Immunostimulants for preventing respiratory tract infection in children (Review). A reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library. 2011; 6.
  10. Esposito S et al. Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study. Int J Environmental Res Public Health 2019; 16 (6): 1065.
  11. Esposito S et al. A randomized placebo-controlled double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J Trans Med 2019; 17 (1): 284.
  12. Yin J et al. Broncho-Vaxom in pediatric recurrent respiratory tract infections: A systematic review and meta-analysis. Int Immunopharmacol 2018; 54: 198-209.
  13. Bitar MA, Saade R. The role of OM-85 BV (Broncho-Vaxom) in preventing recurrent acute tonsillitis in children. Int J Pediatr Otorhinolaryngol 2013; 77 (5): 670-3.
  14. Sorokman TV, Moldovan PM, Popeliuk NO et al. Clinical and Immunological Efficacy of OM-85 Bacterial Lysate In Children With Respiratory Tract Infection. Actual Infectology 2020; 8: 18-24. doi: 10.22141/2312-413x.8.2.2020.199731
  15. Berber A, Del-Rio-Navarro BE. Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections in children that attend day-care centers. Health Econ Rev 2019; 9 (1): 12.
  16. Bodemer C et al. Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study PloS One 2017; 12 (3): e0161555.
  17. Triantafillou V et al. Broncho VaxomR (OM 85 BV) soluble components stimulate sinonasal innate immunity. Int Forum Allergy Rhinol 2019.
  18. Геппе Н.А. и др. Острые инфекции дыхательных путей у детей. Диагностика, лечение и профилактика: клиническое руководство. М.: МЕдКом-Про, 2018.
  19. Fokkens WJ et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology 2020.

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74329 от 19.11.2018 г.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies